Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

G. W. Hogeland, Susan Swindells, J. C. McNabb, A. D M Kashuba, Gary C Yee, C. M. Lindley

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Limited data are available about the effect of steady-state lopinavir and ritonavir (LPV/r) on bupropion pharmacokinetics. As patients may benefit by using these two agents in combination, this study determined the extent and direction of this drug-drug interaction. Twelve healthy volunteers received a single 100 mg dose of sustained-release bupropion before and after 2 weeks of treatment with LPV/r 400 mg/100 mg twice daily. Pharmacokinetics profiles were determined on days 1 and 30 for bupropion and hydroxybupropion and days 29 and 30 for LPV/r. LPV/r administration significantly decreased bupropion maximum plasma concentration (Cmax) by 57% (90% confidence interval (CI), 38-76%; P<0.01) and area under the curve (AUC)∞ by 57% (90% CI, 32-83%; P<0.01). Hydroxybupropion Cmax and AUC∞ decreased by 31% (90% CI, 7-55%; P<0.01) and by 50% (90% CI, 34-65%; P<0.01), respectively. No significant changes in the pharmacokinetics of LPV/r were found following administration of a single dose of bupropion. Concurrent use of LPV/r and bupropion resulted in decreased exposure to bupropion and its active metabolite hydroxybupropion that may necessitate as much as a 100% dose increase of bupropion. A probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP-glucuronosyltransferase enzymes. LPV/r exposure is unaffected by a single dose of bupropion.

Original languageEnglish (US)
Pages (from-to)69-75
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume81
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Lopinavir
Bupropion
Ritonavir
Healthy Volunteers
Confidence Intervals
Pharmacokinetics
Area Under Curve
Glucuronosyltransferase
Drug Interactions

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. / Hogeland, G. W.; Swindells, Susan; McNabb, J. C.; Kashuba, A. D M; Yee, Gary C; Lindley, C. M.

In: Clinical Pharmacology and Therapeutics, Vol. 81, No. 1, 01.01.2007, p. 69-75.

Research output: Contribution to journalArticle

Hogeland, G. W. ; Swindells, Susan ; McNabb, J. C. ; Kashuba, A. D M ; Yee, Gary C ; Lindley, C. M. / Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. In: Clinical Pharmacology and Therapeutics. 2007 ; Vol. 81, No. 1. pp. 69-75.
@article{d1381b53f08944ab9903af3dde2166c9,
title = "Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects",
abstract = "Limited data are available about the effect of steady-state lopinavir and ritonavir (LPV/r) on bupropion pharmacokinetics. As patients may benefit by using these two agents in combination, this study determined the extent and direction of this drug-drug interaction. Twelve healthy volunteers received a single 100 mg dose of sustained-release bupropion before and after 2 weeks of treatment with LPV/r 400 mg/100 mg twice daily. Pharmacokinetics profiles were determined on days 1 and 30 for bupropion and hydroxybupropion and days 29 and 30 for LPV/r. LPV/r administration significantly decreased bupropion maximum plasma concentration (Cmax) by 57{\%} (90{\%} confidence interval (CI), 38-76{\%}; P<0.01) and area under the curve (AUC)∞ by 57{\%} (90{\%} CI, 32-83{\%}; P<0.01). Hydroxybupropion Cmax and AUC∞ decreased by 31{\%} (90{\%} CI, 7-55{\%}; P<0.01) and by 50{\%} (90{\%} CI, 34-65{\%}; P<0.01), respectively. No significant changes in the pharmacokinetics of LPV/r were found following administration of a single dose of bupropion. Concurrent use of LPV/r and bupropion resulted in decreased exposure to bupropion and its active metabolite hydroxybupropion that may necessitate as much as a 100{\%} dose increase of bupropion. A probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP-glucuronosyltransferase enzymes. LPV/r exposure is unaffected by a single dose of bupropion.",
author = "Hogeland, {G. W.} and Susan Swindells and McNabb, {J. C.} and Kashuba, {A. D M} and Yee, {Gary C} and Lindley, {C. M.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1038/sj.clpt.6100027",
language = "English (US)",
volume = "81",
pages = "69--75",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

AU - Hogeland, G. W.

AU - Swindells, Susan

AU - McNabb, J. C.

AU - Kashuba, A. D M

AU - Yee, Gary C

AU - Lindley, C. M.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Limited data are available about the effect of steady-state lopinavir and ritonavir (LPV/r) on bupropion pharmacokinetics. As patients may benefit by using these two agents in combination, this study determined the extent and direction of this drug-drug interaction. Twelve healthy volunteers received a single 100 mg dose of sustained-release bupropion before and after 2 weeks of treatment with LPV/r 400 mg/100 mg twice daily. Pharmacokinetics profiles were determined on days 1 and 30 for bupropion and hydroxybupropion and days 29 and 30 for LPV/r. LPV/r administration significantly decreased bupropion maximum plasma concentration (Cmax) by 57% (90% confidence interval (CI), 38-76%; P<0.01) and area under the curve (AUC)∞ by 57% (90% CI, 32-83%; P<0.01). Hydroxybupropion Cmax and AUC∞ decreased by 31% (90% CI, 7-55%; P<0.01) and by 50% (90% CI, 34-65%; P<0.01), respectively. No significant changes in the pharmacokinetics of LPV/r were found following administration of a single dose of bupropion. Concurrent use of LPV/r and bupropion resulted in decreased exposure to bupropion and its active metabolite hydroxybupropion that may necessitate as much as a 100% dose increase of bupropion. A probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP-glucuronosyltransferase enzymes. LPV/r exposure is unaffected by a single dose of bupropion.

AB - Limited data are available about the effect of steady-state lopinavir and ritonavir (LPV/r) on bupropion pharmacokinetics. As patients may benefit by using these two agents in combination, this study determined the extent and direction of this drug-drug interaction. Twelve healthy volunteers received a single 100 mg dose of sustained-release bupropion before and after 2 weeks of treatment with LPV/r 400 mg/100 mg twice daily. Pharmacokinetics profiles were determined on days 1 and 30 for bupropion and hydroxybupropion and days 29 and 30 for LPV/r. LPV/r administration significantly decreased bupropion maximum plasma concentration (Cmax) by 57% (90% confidence interval (CI), 38-76%; P<0.01) and area under the curve (AUC)∞ by 57% (90% CI, 32-83%; P<0.01). Hydroxybupropion Cmax and AUC∞ decreased by 31% (90% CI, 7-55%; P<0.01) and by 50% (90% CI, 34-65%; P<0.01), respectively. No significant changes in the pharmacokinetics of LPV/r were found following administration of a single dose of bupropion. Concurrent use of LPV/r and bupropion resulted in decreased exposure to bupropion and its active metabolite hydroxybupropion that may necessitate as much as a 100% dose increase of bupropion. A probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP-glucuronosyltransferase enzymes. LPV/r exposure is unaffected by a single dose of bupropion.

UR - http://www.scopus.com/inward/record.url?scp=33846039806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846039806&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100027

DO - 10.1038/sj.clpt.6100027

M3 - Article

C2 - 17186001

AN - SCOPUS:33846039806

VL - 81

SP - 69

EP - 75

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -